Vedolizumab biosimilar(Samsung Bioepis Co Ltd)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameVedolizumab biosimilar(Samsung Bioepis Co Ltd)
Drug Alias NameSB36SB-36
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsMucosal addressin cell adhesion molecule-1 inhibitors
TargetsIntegrin alpha-4/beta-7Mucosal addressin cell adhesion molecule-1
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSandozSamsung Bioepis Co Ltd
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A